Novavax, Inc. (NVV1.F)
EUR 8.74
(0.66%)
EUR 8.74
(0.66%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -487.39 Million USD | 23.1% |
| 2022 | -633.76 Million USD | 62.42% |
| 2021 | -1.68 Billion USD | -304.73% |
| 2020 | -416.71 Million USD | -200.63% |
| 2019 | -114.83 Million USD | 20.3% |
| 2018 | -164.4 Million USD | -1.29% |
| 2017 | -159.88 Million USD | 36.19% |
| 2016 | -258.49 Million USD | -71.15% |
| 2015 | -150.71 Million USD | -86.51% |
| 2014 | -78.36 Million USD | -70.4% |
| 2013 | -49.2 Million USD | -78.03% |
| 2012 | -27.78 Million USD | -40.14% |
| 2011 | -19.83 Million USD | 43.76% |
| 2010 | -34.77 Million USD | 4.42% |
| 2009 | -36.89 Million USD | -14.47% |
| 2008 | -33.46 Million USD | -6.47% |
| 2007 | -30.27 Million USD | -38.27% |
| 2006 | -20.74 Million USD | -31.4% |
| 2005 | -2.52 Million USD | 48.96% |
| 2004 | -21.41 Million USD | -119.55% |
| 2003 | -14.86 Million USD | 27.19% |
| 2002 | -20.42 Million USD | -254.14% |
| 2001 | -5.76 Million USD | 52.54% |
| 2000 | -12.14 Million USD | -189.24% |
| 1999 | -4.2 Million USD | 19.23% |
| 1998 | -4.9 Million USD | -10.64% |
| 1997 | -4.5 Million USD | 11.32% |
| 1996 | -5.2 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 179.86 Million USD | 239.39% |
| 2024 Q1 | -129.03 Million USD | 20.25% |
| 2023 Q4 | -161.79 Million USD | -37.94% |
| 2023 Q3 | -117.29 Million USD | -265.07% |
| 2023 Q2 | 71.05 Million USD | 125.44% |
| 2023 Q1 | -279.36 Million USD | -55.28% |
| 2023 FY | - USD | 23.1% |
| 2022 Q3 | -153.62 Million USD | 69.03% |
| 2022 FY | - USD | 62.42% |
| 2022 Q1 | 217.35 Million USD | 126.35% |
| 2022 Q2 | -496.11 Million USD | -328.25% |
| 2022 Q4 | -179.9 Million USD | -17.11% |
| 2021 Q1 | -212.9 Million USD | -16.44% |
| 2021 Q3 | -307.27 Million USD | 11.15% |
| 2021 Q2 | -345.82 Million USD | -62.43% |
| 2021 FY | - USD | -304.73% |
| 2021 Q4 | -824.97 Million USD | -168.48% |
| 2020 FY | - USD | -200.63% |
| 2020 Q2 | -13.79 Million USD | 38.23% |
| 2020 Q3 | -192.16 Million USD | -1293.37% |
| 2020 Q4 | -182.85 Million USD | 4.84% |
| 2020 Q1 | -22.32 Million USD | 22.22% |
| 2019 Q2 | -35.1 Million USD | 9.18% |
| 2019 FY | - USD | 20.3% |
| 2019 Q4 | -28.7 Million USD | 13.07% |
| 2019 Q1 | -38.65 Million USD | 16.9% |
| 2019 Q3 | -33.01 Million USD | 5.94% |
| 2018 FY | - USD | -1.29% |
| 2018 Q4 | -46.51 Million USD | -15.6% |
| 2018 Q3 | -40.23 Million USD | -0.1% |
| 2018 Q2 | -40.19 Million USD | 3.74% |
| 2018 Q1 | -41.75 Million USD | 12.61% |
| 2017 Q4 | -47.78 Million USD | -25.46% |
| 2017 Q1 | -38.7 Million USD | 28.39% |
| 2017 FY | - USD | 36.19% |
| 2017 Q2 | -39.41 Million USD | -1.84% |
| 2017 Q3 | -38.08 Million USD | 3.37% |
| 2016 FY | - USD | -71.15% |
| 2016 Q3 | -61.07 Million USD | 17.91% |
| 2016 Q2 | -74.39 Million USD | 1.15% |
| 2016 Q4 | -54.04 Million USD | 11.51% |
| 2016 Q1 | -75.26 Million USD | 4.61% |
| 2015 Q2 | -20.82 Million USD | 10.04% |
| 2015 FY | - USD | -86.51% |
| 2015 Q4 | -78.9 Million USD | -148.92% |
| 2015 Q1 | -23.14 Million USD | 26.9% |
| 2015 Q3 | -31.69 Million USD | -52.24% |
| 2014 Q2 | -16.83 Million USD | -25.71% |
| 2014 Q3 | -18.64 Million USD | -10.71% |
| 2014 FY | - USD | -70.4% |
| 2014 Q4 | -31.66 Million USD | -69.86% |
| 2014 Q1 | -13.39 Million USD | -2.49% |
| 2013 Q3 | -14.56 Million USD | -18.02% |
| 2013 FY | - USD | -78.03% |
| 2013 Q2 | -12.33 Million USD | -23.32% |
| 2013 Q1 | -10 Million USD | -11.84% |
| 2013 Q4 | -13.06 Million USD | 10.25% |
| 2012 FY | - USD | -40.14% |
| 2012 Q4 | -8.94 Million USD | -39.69% |
| 2012 Q2 | -5.41 Million USD | 23.04% |
| 2012 Q1 | -7.03 Million USD | -84.37% |
| 2012 Q3 | -6.4 Million USD | -18.37% |
| 2011 Q1 | -6.97 Million USD | -45.63% |
| 2011 FY | - USD | 43.76% |
| 2011 Q4 | -3.81 Million USD | -7.8% |
| 2011 Q3 | -3.53 Million USD | 35.5% |
| 2011 Q2 | -5.48 Million USD | 21.37% |
| 2010 Q3 | -10.18 Million USD | -11.52% |
| 2010 Q2 | -9.13 Million USD | 18.17% |
| 2010 Q4 | -4.78 Million USD | 52.97% |
| 2010 Q1 | -11.15 Million USD | 20.39% |
| 2010 FY | - USD | 4.42% |
| 2009 Q2 | -7.06 Million USD | -18.43% |
| 2009 Q1 | -5.96 Million USD | 32.97% |
| 2009 FY | - USD | -14.47% |
| 2009 Q4 | -14.01 Million USD | -61.89% |
| 2009 Q3 | -8.65 Million USD | -22.57% |
| 2008 Q2 | -8.2 Million USD | -17.29% |
| 2008 Q1 | -6.99 Million USD | -112.11% |
| 2008 FY | - USD | -6.47% |
| 2008 Q3 | -9.72 Million USD | -18.54% |
| 2008 Q4 | -8.89 Million USD | 8.46% |
| 2007 Q4 | -3.29 Million USD | 63.0% |
| 2007 Q3 | -8.9 Million USD | -3.58% |
| 2007 Q2 | -8.59 Million USD | 3.22% |
| 2007 Q1 | -8.88 Million USD | -39.94% |
| 2007 FY | - USD | -38.27% |
| 2006 Q1 | -4.01 Million USD | -35.64% |
| 2006 Q4 | -6.34 Million USD | -17.79% |
| 2006 FY | - USD | -31.4% |
| 2006 Q3 | -5.39 Million USD | 12.13% |
| 2006 Q2 | -6.13 Million USD | -52.63% |
| 2005 Q4 | -2.96 Million USD | -39.83% |
| 2005 FY | - USD | 48.96% |
| 2005 Q3 | -2.11 Million USD | 49.42% |
| 2005 Q2 | -4.18 Million USD | 43.32% |
| 2005 Q1 | -7.39 Million USD | 18.69% |
| 2004 Q4 | -9.08 Million USD | 24.32% |
| 2004 Q1 | -4.24 Million USD | -54.59% |
| 2004 FY | - USD | -119.55% |
| 2004 Q3 | -12.01 Million USD | -81.09% |
| 2004 Q2 | -6.63 Million USD | -56.12% |
| 2003 Q3 | -2.64 Million USD | 39.09% |
| 2003 FY | - USD | 27.19% |
| 2003 Q1 | -5.12 Million USD | -11.06% |
| 2003 Q2 | -4.34 Million USD | 15.08% |
| 2003 Q4 | -2.74 Million USD | -3.74% |
| 2002 Q3 | -6.19 Million USD | -22.29% |
| 2002 Q2 | -5.23 Million USD | -3.25% |
| 2002 Q4 | -4.61 Million USD | 23.89% |
| 2002 Q1 | -5.17 Million USD | -124.52% |
| 2002 FY | - USD | -254.14% |
| 2001 Q2 | -747 Thousand USD | 45.43% |
| 2001 Q1 | -1.36 Million USD | 71.47% |
| 2001 Q3 | -1.51 Million USD | -102.54% |
| 2001 FY | - USD | 52.54% |
| 2001 Q4 | -2.13 Million USD | -41.24% |
| 2000 Q2 | -2.72 Million USD | -101.26% |
| 2000 Q3 | -3.27 Million USD | -20.2% |
| 2000 Q4 | -4.79 Million USD | -46.62% |
| 2000 FY | - USD | -189.24% |
| 2000 Q1 | -1.35 Million USD | -35.3% |
| 1999 Q2 | -800 Thousand USD | 0.0% |
| 1999 Q4 | -1 Million USD | 37.5% |
| 1999 Q3 | -1.6 Million USD | -100.0% |
| 1999 Q1 | -800 Thousand USD | 50.0% |
| 1999 FY | - USD | 19.23% |
| 1998 Q2 | -1.3 Million USD | -44.44% |
| 1998 Q3 | -1.2 Million USD | 0.0% |
| 1998 Q4 | -1.6 Million USD | -23.08% |
| 1998 FY | - USD | -10.64% |
| 1998 Q1 | -800 Thousand USD | 10.0% |
| 1997 Q2 | -1.4 Million USD | -40.0% |
| 1997 Q3 | -1.1 Million USD | 14.29% |
| 1997 FY | - USD | 11.32% |
| 1997 Q4 | -1 Million USD | 16.67% |
| 1997 Q1 | -1 Million USD | 41.18% |
| 1996 Q3 | -900 Thousand USD | 25.0% |
| 1996 Q1 | -1 Million USD | 0.0% |
| 1996 Q4 | -1.7 Million USD | -88.89% |
| 1996 Q2 | -1.2 Million USD | -9.09% |
| 1996 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| BioNTech SE | 1.08 Billion EUR | 144.813% |
| CureVac N.V. | -234.09 Million EUR | -108.206% |
| Biotest Aktiengesellschaft | 179 Million EUR | 372.285% |
| Biotest Aktiengesellschaft | 179 Million EUR | 372.285% |
| BRAIN Biotech AG | -2.38 Million EUR | -20318.517% |
| Formycon AG | 81.05 Million EUR | 701.323% |
| Heidelberg Pharma AG | -18.7 Million EUR | -2505.475% |
| Medigene AG | -14.58 Million EUR | -3241.721% |